Skip to content

Comparsion of D2 verus D3 surgical procedure outcome in locally advanced gastric cancer patients following perioperative chemotherapy

Phase III Randomised controlled trial comparing D2 versus D3 lymphadenectomy on outcomes of non-metastatic, resectable, but locally advanced, gastric cancer following neoadjuvant (perioperative) chemotherapy (ELANCe trial) - ELANCe

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/08/003882
Enrollment
287
Registered
2013-08-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Gastric Cancer

Interventions

Intervention1: D3 lymphadenectomy: D3 is Extended Lymphadenectomy The difference between a D3 and a D2 plus para-aortic lymph node dissection is that in a D3, in addition to the lymph nodes removed

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -ECOG performance status of 0 â?? 1 in patients deemed fit to undergo surgery at the pre-anaesthetic check -Histologically proven gastric adenocarcinoma -No evidence of distant metastases, or locally advanced inoperable disease, as evaluated by computed tomography, chest radiography, ultrasonography, and / or laparotomy -Patient able to provide valid informed consent -Patient completed at least 1 cycle of neoadjuvant chemotherapy

Exclusion criteria

Exclusion criteria: Presence of any 1 of the following: -Previous or concomitant other cancer -Primary Oesophageal involvement extending to the stomach -Distant hepatic / extrahepatic disease discovered on laparotomy -Gross local disease in the porta precluding a curative resection -Patient did not consent for the trial

Design outcomes

Secondary

MeasureTime frame
Disease-free survival Timepoint: date of diagnosis to date of death /recurrence

Primary

MeasureTime frame
primary endpoint:Overall Survival Timepoint: date of diagnosis to Date of death or last follow-up

Countries

India

Contacts

Public ContactDr Bhawna Sirohi

Tata Memorial Hospital

bhawna.sirohi13@gmail.com09930033980

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026